93 related articles for article (PubMed ID: 16920253)
1. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; Malmström PU; de Kok JB
Eur Urol; 2007 Feb; 51(2):416-22; discussion 422-3. PubMed ID: 16920253
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence.
Schultz IJ; De Kok JB; Witjes JA; Babjuk M; Willems JL; Wester K; Swinkels DW; Tjalsma H
Anticancer Res; 2007; 27(2):1051-8. PubMed ID: 17465243
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
4. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
[TBL] [Abstract][Full Text] [Related]
5. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study.
Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; de Kok JB; Malmström PU
Int J Cancer; 2006 Oct; 119(8):1915-9. PubMed ID: 16721812
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
Rouprêt M; Hupertan V; Yates DR; Comperat E; Catto JW; Meuth M; Lackmichi A; Ricci S; Lacave R; Gattegno B; Richard F; Hamdy FC; Cussenot O
BJU Int; 2008 Jun; 101(11):1448-53. PubMed ID: 18325051
[TBL] [Abstract][Full Text] [Related]
7. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
Kitsukawa S; Aoyagi T; Noda K; Ito T; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T
Hinyokika Kiyo; 2008 Feb; 54(2):101-6. PubMed ID: 18323166
[TBL] [Abstract][Full Text] [Related]
9. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.
Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH
Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511
[TBL] [Abstract][Full Text] [Related]
10. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
[TBL] [Abstract][Full Text] [Related]
11. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
12. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
[TBL] [Abstract][Full Text] [Related]
13. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
[TBL] [Abstract][Full Text] [Related]
14. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
[TBL] [Abstract][Full Text] [Related]
15. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.
Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Ntinis A; Moreas I; Vasou O; Koutselini H; Patsouris E
Anticancer Res; 2009 Oct; 29(10):4163-7. PubMed ID: 19846967
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
17. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
18. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
19. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
20. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
